Biogen Idec develops, produces and sells biopharmaceutical products, based on recombinant DNA technologies in particular. With a research centre in Cambridge, Massachusetts (USA), production facilities in America and the Netherlands and a global sales organisation, Biogen currently employs more than 2,000 people. The company concentrates its research on the development of innovative products in the area of multiple sclerosis, inflammatory, respiratory, kidney and heart diseases, as well as genetic therapy.
